PTGS1 and cardiovascular disorder: The inhibition of pro-aggregatory effects of TxA2 through acetylation of COX-1 in platelets is the pharmacological basis for aspirin, used in association with a P2Y12 receptor antagonist in dual antiplatelet therapy to treat cardiovascular diseases and prevent the recurrence of major cardiovascular events due to thrombosis (Schrör and Rauch, 2015).